Antenatal Magnesium Sulphate in High-Risk Preterm Patients
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Cerebral Palsy, Magnesium Sulfate Overdose
In brief
The goal of this clinical trial is to evaluate whether antenatal magnesium sulphate reduces the risk of cerebral palsy in infants born to women at high risk of preterm birth. It will also assess the safety of magnesium sulfate for both the mother and the neonate. The main question it aims to answer is whether magnesium sulphate given before anticipated preterm delivery decreases the incidence of cerebral palsy without causing significant maternal or neonatal adverse effects. Researchers will compare magnesium sulphate with a placebo in women at high risk of preterm birth between 32 and 35 weeks of gestation. Participants will be randomly assigned to receive either intravenous magnesium sulphate or a placebo before delivery, and maternal and neonatal outcomes will be followed after birth, including neurodevelopmental assessment of the infant.
Key facts
- Study ID
- NCT07524972
- Run by
- Cairo University
- People needed
- 138
- Starts
- 2026-05-01
- Expected to finish
- 2028-05-30
- Last updated by the study team
- 2026-04-13
Who can join
Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Suez Canal University — Ismailia, Ismailia Governorate, Egypt (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.